NCT06585878View on ClinicalTrials.gov

A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Renal Cell CarcinomaRCCKidney Cancer
Interventions
RADIATION

Stereotactic Ablative Radiotherapy (SABR)

Without altering the patients' systemic treatment plans, patients who meet the inclusion criteria after MDT discussion will receive SBRT radiotherapy for all lesions/all metastatic lesions based on the guideline-recommended medications. The radiotherapy plan is based on the SABR-COMET protocol and Timmerman's constraints.

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT06585878 - A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter